Notice2023-14308
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 7, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 129 (Friday, July 7, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 129 (Friday, July 7, 2023)]
[Notices]
[Page 43366]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-14308]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Chris Kornak at 240-
627-3705 or <a href="/cdn-cgi/l/email-protection#03606b716a702d686c716d6268436d6a6b2d646c75"><span class="__cf_email__" data-cfemail="e88b809a819bc683879a868983a8868180c68f879e">[email protected]</span></a>. A signed Confidential Disclosure
Agreement will be required to receive copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Dual-Germline Antibody Engager Chimeric HIV-1 Immunogens
Description of Technology: Despite four decades of intensive
research, a safe and effective HIV-1 vaccine remains elusive due to the
extreme difficulty in eliciting broadly neutralizing antibodies
(bNAbs), which recognize and block HIV-1 from entering healthy cells.
Only rare natural HIV-1 envelopes (Envs) promote the activation and
expansion of na[iuml]ve B cells expressing unmutated germline
antibodies of various bNAb lineages, but they typically do so for a
single lineage for the same neutralization site. To overcome this
challenge, NIAID has designed and characterized two chimeric HIV-1 Env
immunogens capable of simultaneously engaging multiple germline bNAb
lineages. Both chimeric Env immunogens maintain native-like folding and
engage two lineages of germline bNAbs directed against two independent
sites of HIV-1 vulnerability.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Immunization: The dual-germline engager HIV-1 immunogens
could be employed during the priming phase of an HIV vaccine to trigger
multiple bNAb lineages simultaneously, resulting in a multi-target
protective antibody response.
<bullet> Clinical Treatment: The dual-germline engager HIV-1
immunogens could serve as an alternative to current anti-retrovirals or
incorporated into current HIV treatment strategies.
Competitive Advantages:
<bullet> Dual-germline engager HIV-1 Env immunogens are inherently
superior to the currently available single-germline engagers for
eliciting bNAbs.
<bullet> The chimeric design could be expanded to generate HIV-1
Env trimers with even more germline bNAb specificities to enable a
broader immunogenic response against HIV.
Inventors: Peng Zhang, Ph.D., Paolo Lusso, M.D., Ph.D., both of
NIAID.
Publications: Publication pending.
Intellectual Property: HHS Reference No. E-140-2022; US Provisional
Application No. 63/397,789.
Licensing Contact: To license this technology, please contact Chris
Kornak at 240-627-3705 or <a href="/cdn-cgi/l/email-protection#3152594358421f5a5e435f505a715f58591f565e47"><span class="__cf_email__" data-cfemail="690a011b001a4702061b07080229070001470e061f">[email protected]</span></a>, and reference E-140-
2022.
Collaborative Research Opportunity: The Technology Transfer and
Intellectual Property Office is seeking parties interested in
collaborative research to further develop this technology by
manufacturing non-MRNA virus-like particles incorporating dual germline
engager HIV-1 immunogens and subsequently testing immunogenicity in
non-human primates. For collaboration opportunities, please contact
Chris Kornak; 240-627-3705, <a href="/cdn-cgi/l/email-protection#6b080319021845000419050a002b050203450c041d"><span class="__cf_email__" data-cfemail="64070c160d174a0f0b160a050f240a0d0c4a030b12">[email protected]</span></a>.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-14308 Filed 7-6-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 7, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.